The appendix cancer standard of care.
A clinician summary, anchored to the 2025 appendiceal consensus guidelines, not colorectal protocols.
The appendix cancer standard of care is not the colon cancer standard of care. Appendiceal disease has its own biology, its own grading, and now its own consensus guidelines. This page orients any clinician quickly so a patient reaches the right care early. It is a summary, not a substitute for the full guidelines or for specialist judgment.
The appendix cancer standard of care starts with the right guideline
The current reference is the 2025 consensus guideline for the management of patients with appendiceal tumors (Godfrey et al., Cancer, 2025), developed through a national expert panel on peritoneal surface malignancy. It is published in two parts: Part 1 covers appendiceal tumors without peritoneal involvement, and Part 2 covers appendiceal tumors with peritoneal involvement.
Appendiceal tumors are frequently managed off colorectal templates because that is where they have historically been filed. Those templates do not fit low-grade mucinous biology and can lead to overtreatment or the wrong referral. The appendiceal consensus is the more appropriate reference, and it is the one this summary follows.
Classification and grading
Appendiceal neoplasms span a wide biological range. Grading is three-tier (G1, G2, G3). Grade 2 is its own category and should not be collapsed into high-grade. Pseudomyxoma peritonei is a clinical syndrome of mucinous peritoneal spread, not a single diagnosis, and it is usually appendiceal in origin.
LAMN
Low-grade appendiceal mucinous neoplasm. Can seed the peritoneum even when confined-appearing.
HAMN
High-grade appendiceal mucinous neoplasm. Less common, more aggressive behavior.
Mucinous adenocarcinoma
Graded G1 to G3. The grade drives prognosis and treatment intensity.
Non-mucinous adenocarcinoma
Behaves closer to colorectal adenocarcinoma than the mucinous subtypes.
Goblet cell adenocarcinoma
A distinct amphicrine tumor, graded on its own system. Not a neuroendocrine tumor.
Signet ring cell
A high-grade feature associated with more aggressive disease.
Neuroendocrine tumor
Appendiceal NET is managed on a separate pathway from the epithelial tumors above.
Peritoneal disease: CRS and HIPEC
For appendiceal tumors with peritoneal spread, the mainstay is complete cytoreductive surgery (CRS), often combined with hyperthermic intraperitoneal chemotherapy (HIPEC), performed at an experienced peritoneal surface malignancy center. The completeness of cytoreduction is the strongest modifiable prognostic factor, so the priority is getting the patient to a high-volume center before a non-therapeutic operation limits future options.
Peritoneal disease burden is scored intraoperatively with the Peritoneal Cancer Index. Because the abdomen is the field that matters, early referral and a considered first operation change what is possible later. A rushed second surgery in the wrong setting can close doors that a specialist center would have kept open.
Systemic therapy and molecular testing
Systemic chemotherapy has a limited and selective role. Much of it is extrapolated from colorectal regimens, and low-grade mucinous disease generally does not respond well. Decisions are individualized and best made with a center that treats appendiceal cancer regularly.
Molecular profiling is worth obtaining where possible. KRAS and GNAS are the common drivers in mucinous appendiceal tumors, with TP53, MSI, and HER2 relevant in subsets. These results inform trial eligibility and, in GNAS-driven disease, emerging targeted approaches.
Surveillance
Follow-up combines cross-sectional imaging with tumor markers, commonly CEA, CA19-9, and CA125. Surveillance intensity tracks with grade and stage. Rising markers or new peritoneal findings warrant prompt re-referral to the treating peritoneal center.
A note for non-specialists
Most clinicians will see very few appendiceal cancers in a career, so it is normal not to carry the details. The one point worth remembering is that the appendix cancer standard of care lives in its own guidelines and is delivered at peritoneal surface malignancy centers, not in a general colorectal pathway. When a case appears, the highest-value move is a specialist referral before any further abdominal surgery. Everything else, the grading, the systemic choices, and the surveillance schedule, can be worked out with a center that treats this disease regularly. Getting the first steps right is what protects the patient’s options.
Have a patient who needs this care?
The most important step in the appendix cancer standard of care is early referral to a peritoneal surface malignancy center. We can help you find one.
How to Refer a Patient Treatment Overview